Company profile: Integrated DNA Technologies
1.1 - Company Overview
Company description
- Provider of custom DNA and RNA oligonucleotides with various modifications; CRISPR-Cas9 reagents and tools for genome editing; gBlocks double-stranded gene fragments (125-3000 bp) for gene assembly, qPCR, and NGS; PrimeTime qPCR probes with dye and quencher options for multiplex gene expression analysis; and xGen DNA library prep kits for next-generation sequencing.
Products and services
- GBlocks Gene Fragments: Research-grade, double-stranded DNA fragments (125–3000 bp) synthesized for gene assembly, qPCR, NGS, and other molecular biology applications
- Custom DNA Oligos: Custom-engineered, synthesized DNA oligonucleotides offering over 1400 available modifications, produced in various lengths and formats for precise research applications
- XGenâ„¢ DNA Library Prep Kits: Workflow-optimized kits for preparing DNA libraries from various sample types for next-generation sequencing workflows
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Integrated DNA Technologies
Ginkgo Bioworks
HQ: United States
Website
- Description: Provider of biological engineering products and custom microbes, designing, engineering, developing, testing, and licensing organisms. Discovers molecules for flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals, and provides probiotic bacteria.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ginkgo Bioworks company profile →
Genomas
HQ: United States
Website
- Description: Provider of DNA-guided medicine products that bring personalized prescription of drugs to clinical practice, targeting treatments for mental illness, diabetes, and cardiovascular disease, and aimed at eliminating trial-and-error prescribing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genomas company profile →
Lentigen Technology
HQ: United States
Website
- Description: Provider of gene delivery technologies and CDMO services for cell and gene therapy products, offering lentiviral vector technology for therapeutic, vaccine, and research applications; lentiviral vector design, evaluation, and scalable manufacturing; process development and clinical manufacturing; assay development via automated flow cytometry; and regulatory support from pre-IND to approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lentigen Technology company profile →
Airna
HQ: United States
Website
- Description: Provider of RNA editing technologies and therapeutics, including the RESTORE+ RNA editing platform to optimize sequence, chemistry, and delivery for precise RNA editing to treat rare and common diseases. Offers RNA editing therapeutics for alpha-1 antitrypsin deficiency (AATD) and a pipeline addressing diseases with high unmet need.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Airna company profile →
Feldan Therapeutics
HQ: Canada
Website
- Description: Provider of a patented peptide-based technology platform for delivering therapeutic compounds into cells, including the Feldan Shuttle, and FLD-103, an intralesional treatment for basal cell carcinoma that targets BCC cells by disrupting an intracellular component involved in the disease’s pathophysiology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Feldan Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Integrated DNA Technologies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Integrated DNA Technologies
2.2 - Growth funds investing in similar companies to Integrated DNA Technologies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Integrated DNA Technologies
4.2 - Public trading comparable groups for Integrated DNA Technologies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →